These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 8250523)

  • 1. Expanded clinical trials of treatments for multiple sclerosis. The Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis of The National Multiple Sclerosis Society.
    Whitaker JN
    Ann Neurol; 1993 Dec; 34(6):755-6. PubMed ID: 8250523
    [No Abstract]   [Full Text] [Related]  

  • 2. Expanded clinical trials of treatments for multiple sclerosis: copolymer 1 (COP-1) treatment investigational new drug (IND) program.
    Stark Y
    Ann Neurol; 1994 Jul; 36(1):114-5. PubMed ID: 8024251
    [No Abstract]   [Full Text] [Related]  

  • 3. Controversy trails adaptive clinical trials.
    Goozner M
    J Natl Cancer Inst; 2012 Sep; 104(18):1347-8. PubMed ID: 22984199
    [No Abstract]   [Full Text] [Related]  

  • 4. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tricky FDA debate: should a risky drug be approved again?
    Mathews AW; Westphal SP
    Wall St J (East Ed); 2006 Feb; ():B1, B4. PubMed ID: 16528879
    [No Abstract]   [Full Text] [Related]  

  • 6. Adaptive trials receive boost.
    Jones D
    Nat Rev Drug Discov; 2010 May; 9(5):345-8. PubMed ID: 20414200
    [No Abstract]   [Full Text] [Related]  

  • 7. Slow start to phase 0 as researchers debate value.
    Twombly R
    J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150
    [No Abstract]   [Full Text] [Related]  

  • 8. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS.
    Lublin FD; Reingold SC
    Ann Neurol; 2001 May; 49(5):677-81. PubMed ID: 11357961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical development of atypical antipsychotics: research design and evaluation. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():10-6. PubMed ID: 9766614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovative strategies for early clinical R&D.
    Butz RF; Morelli G
    IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient group seeks overhaul of FDA clinical trial system in court.
    Hede K
    J Natl Cancer Inst; 2006 Sep; 98(18):1268-70. PubMed ID: 16985242
    [No Abstract]   [Full Text] [Related]  

  • 12. Accelerated approval regulations may need overhaul, panel suggests.
    Finkelstein JB
    J Natl Cancer Inst; 2005 Dec; 97(24):1802-4. PubMed ID: 16368938
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravenous immune globulin for multiple sclerosis.
    Tecnologica MAP Suppl; 1998 Aug; ():3-5. PubMed ID: 10342975
    [No Abstract]   [Full Text] [Related]  

  • 14. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

  • 16. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated approval seen as triumph and roadblock for cancer drugs.
    Susman E
    J Natl Cancer Inst; 2004 Oct; 96(20):1495-6. PubMed ID: 15494596
    [No Abstract]   [Full Text] [Related]  

  • 18. Cancer drugs. Weighing the risks and benefits.
    Bren L
    FDA Consum; 2007; 41(1):10-9. PubMed ID: 17342832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies in multiple sclerosis.
    Farrell R; Heaney D; Giovannoni G
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):797-816. PubMed ID: 16262563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
    Schultheis LW; Rappaport BA
    Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.